Unmet Needs and Advice for Community Oncologists Treating Patients With NDMM
Natalie Callander, MD, offers advice for community oncologists and discusses unmet needs in treating transplant-preferred patients with newly diagnosed MM.
Recent Data on Other Regimens for Newly Diagnosed Multiple Myeloma
An overview of recent data from the SKylaRK and GMMG-HD7 trials evaluating non-daratumumab-based regimens for patients with transplant-preferred NDMM.
Impact of Quadruplet Therapy on Patients with High-Risk NDMM
Natalie Callander, MD, details findings from her study, evaluating the impact of quadruplet therapy on newly diagnosed patients with high-risk multiple myeloma.
Subgroup Analysis of MASTER Trial for Newly Diagnosed MM
Insights on how the subgroup analysis of the MASTER trial informs the role of autologous stem cell transplantation and the use of quadruplet therapy for elderly patients.
GRIFFIN Trial: D-RVd in Transplant-Preferred Newly Diagnosed MM
Natalie Callander, MD, reviews the results and quality-of-life outcomes from the GRIFFIN trial on Dara-RVd for patients with transplant-eligible NDMM.
Overview of Treatments and Role of Stem Cell Transplantation for Patients With NDMM
An expert oncologist discusses the role of stem cell transplantation and currently available therapies for the treatment of newly diagnosed multiple myeloma.
Patient Profile: A 61-Year-Old Woman with Transplant-Preferred Newly Diagnosed Multiple Myeloma
Natalie Callander, MD, presents the case of a 61-year-old woman with transplant-preferred newly diagnosed multiple myeloma (NDMM) and offers her initial impressions.
Clinical Pearls for the Management of MM
An expert in multiple myeloma provides clinical pearls for disease management from initial diagnosis through multiple lines of therapy.
The Evolving Treatment Landscape in MM
Dr. Natalie Callander describes promising new treatment approaches for patients with multiple myeloma.
Considerations for Third-Line Therapy in MM
An expert in multiple myeloma talks through the considerations for treatment selection in the third line for patient with multiple myeloma.
Second-Line Options After ASCT in MM
Dr. Natalie Callander provides insight on selection of second-line therapy after transplant patients with multiple myeloma.
Case Presentation: A 68-Year-Old Man With Multiple Myeloma
Natalie Callander, MD, presents a case of a 68-year-old man with multiple myeloma and reviews first-line treatment options.
A 68-Year-Old Man with Multiple Myeloma
Natalie Callander, MD, presents a case of a 68-year-old man with multiple myeloma.
CAR T-Cell Therapy Appears Promising for Heavily Pretreated Multiple Myeloma
Natalie S. Callander, MD, discusses the role of CAR T-cell therapy as treatment of patients with multiple myeloma.
Updates in the Treatment of Relapsed/Refractory Multiple Myeloma
Natalie S. Callander, MD, Professor of Medicine, University of Wisconsin Carbone Cancer Center, discusses updates in the treatment of relapsed/refractory multiple myeloma.